Article


Phase I Clinical Trials in the Era of Immunotherapy

James C. Kuo

Scientia Clinical Research & Prince of Wales Clinical School, University of New South Wales, Sydney, Australia

Dr. James C. Kuo, Scientia Clinical Research & Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.

Keywords: Immunotherapy; Cancer Care; Oncology

Abstract

Immunotherapy has changed the landscape of cancer care and has become the most promising area of cancer research over the recent years. Various stakeholders anticipate a rapid-fire development of immuneoncology (IO) agents and an accelerated regulatory approval timeline has been modernized with, most notably, the breakthrough therapy designation by the US Food and Drug Administration (FDA) in July 2012. Once biomarkers for novel IO agents are identified, the success in obtaining FDA approval for drugs with breakthrough therapy designation, such as ceritinib and durvalumab, after a single-arm phase I/II trial will be multiplied.

View Full Text | Download PDF

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Total Articles Published

5
6
1


Track Your Article







Highlights


Cient Periodique is a ‘Gold’ open access publisher that aspires to offer absolute free, unrestricted access to the valuable research information

We welcome all the eminent authors to submit your valuable paper

Cient Periodique invites the participation of honourable Editors and Authors

CPQ Journals provide Certificates for publication

Cient Periodique also offers memberships for potential Authors

Best Articles will be appreciated with the provision of corresponding Certificate